Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia

References

• Abdelkader H, Alani AW, Alany RG. (2014). Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 21:87–100.
   PubMed Web of Science ®Google Scholar
• Al-Ahmady ZS, Chaloin O, Kostarelos K. (2014). Monoclonal antibody-targeted, temperature-sensitive liposomes: In vivo tumor chemotherapeutics in combination with mild hyperthermia. J Control Release 196:332–43.
   PubMed Web of Science ®Google Scholar
• Altreuter DH, Dordick JS, Clark DS. (2002). Nonaqueous biocatalytic synthesis of new cytotoxic doxorubicin derivatives: exploiting unexpected differences in the regioselectivity of salt-activated and solubilized subtilisin. J Am Chem Soc 124:1871–6.
   PubMed Web of Science ®Google Scholar
• Becker MW, Jordan CT. (2011). Leukemia stem cells in 2010: Current understanding and future directions. Blood Rev 25:75–81.
   PubMed Web of Science ®Google Scholar
• Bob Löwenberg JDG, Tallman MS, Löwenberg B, et al. (2003). Acute myeloid leukemia. Am Soc Hematol 2003:82–101.
   PubMedGoogle Scholar
• Cheng MJ, Hourigan CS, Smith TJ. (2014). Adult acute myeloid leukemia long-term survivors. J Leuk (Los Angel) 2:135. doi: 10.4172/2329-6917.1000135
   Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14:1777–84.
   PubMed Web of Science ®Google Scholar
• Dinauer N, Balthasar S, Weber C, et al. (2005). Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26:5898–906.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Kramer M, Rollig C, et al. (2014). Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 4:e218.
   PubMed Web of Science ®Google Scholar
• Estey E, Döhner H. (2006). Acute myeloid leukaemia. Lancet 368:1894–907.
   PubMed Web of Science ®Google Scholar
• Florian S, Sonneck K, Hauswirth AW, et al. (2006). Detection of molecular targets on the surface of CD34+/CD38– stem cells in various myeloid malignancies. Leuk Lymphoma 47:207–22.
   PubMed Web of Science ®Google Scholar
• Gebleux R, Casi G. (2016). Antibody-drug conjugates: current status and future perspectives. Pharmacol Ther 167:48–59.
   PubMed Web of Science ®Google Scholar
• Hasan AA, Madkor H, Wageh S. (2013). Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv 20:120–6.
   PubMed Web of Science ®Google Scholar
• He SZ, Busfield S, Ritchie DS, et al. (2015). A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma 56:1406–15.
   PubMed Web of Science ®Google Scholar
• Hong M, Zhu S, Jiang Y, et al. (2009). Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 133:96–102.
   PubMed Web of Science ®Google Scholar
• Institute, N.C., 2016. SEER Cancer Stat Facts: Acute Myeloid Leukemia. http://seer.cancer.gov/statfacts/html/amyl.html [online]. National Cancer Institute. Available from: [Last Accessed 2016].
   Google Scholar
• Jin L, Lee EM, Ramshaw HS, et al. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5:31–42.
   PubMed Web of Science ®Google Scholar
• Kazi KM, Mandal AS, Biswas N, et al. (2010). Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res 1:374–80.
   PubMedGoogle Scholar
• Konopleva MY, Jordan CT. (2011). Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 29:591–9.
   PubMed Web of Science ®Google Scholar
• Laginha K, Mumbengegwi D, Allen T. (2005). Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 1711:25–32.
   PubMed Web of Science ®Google Scholar
• Li B, Zhao W, Zhang X, et al. (2016). Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem 24:5855–60.
   PubMed Web of Science ®Google Scholar
• Li K, Lv XX, Hua F, et al. (2014). Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Int J Cancer 134:692–702.
   PubMed Web of Science ®Google Scholar
• Liu M, Li W, Larregieu CA, et al. (2014). Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Mol Pharm 11:2305–12.
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, et al. (2011). Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 150:2–22.
   PubMed Web of Science ®Google Scholar
• Misaghian N, Ligresti G, Steelman LS, et al. (2009). Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23:25–42.
   PubMed Web of Science ®Google Scholar
• Stone RM, O’Donnell MR, Sekeres MA. (2004). Acute myeloid leukemia. Boston, MA: American Society of Hematology, 98–117.
   Google Scholar
• Rombouts WJ, Martens AC, Ploemacher RE. (2000). Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 14:889–97.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
   PubMed Web of Science ®Google Scholar
• Society AC. 2013. Cancer facts & figures 2013. In A.C. Society (ed.) Atlanta: American Cancer Society.
   Google Scholar
• Sun M, Yang C, Zheng J, et al. (2015). Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater 28:171–82.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. (2005). Drug therapy for acute myeloid leukemia. Blood 106:1154–63.
   PubMed Web of Science ®Google Scholar
• Tallman EM, Stein EM. (2012). Novel and emerging drugs for acute myeloid leukemia. Curr Cancer Drug Targets 12:522–30.
   PubMed Web of Science ®Google Scholar
• Tavano L, Aiello R, Ioele G, et al. (2014). Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties. Colloids Surf B Biointerf 118:7–13.
   PubMed Web of Science ®Google Scholar
• Tavano L, Muzzalupo R, Mauro L, et al. (2013). Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy. Langmuir 29:12638–46.
   PubMed Web of Science ®Google Scholar
• Ten Cate B, Bremer E, De Bruyn M, et al. (2009). A novel AML-selective TRAIL fusion protein that is superior to gemtuzumab ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 23:1389–97.
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Militi S, et al. (2002). Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100:2980–8.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Biondi A, Biagi E, et al. (2014). CD123 AML targeting by chimeric antigen receptors: a novel magic bullet for AML therapeutics?. Oncoimmunology 3:e28835
   PubMed Web of Science ®Google Scholar
• Tsuchikama K, An Z. (2016). Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell [1–14]. doi: 10.1007/s13238-016-0323-0
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, et al. (2011). High levels of CD34 + CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 96:1792–8.
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, et al. (2007). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–77.
   PubMed Web of Science ®Google Scholar
• Yeom S, Shin BS, Han S. (2014). An electron spin resonance study of non-ionic surfactant vesicles (niosomes). Chem Phys Lipids 181:83–9.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chng WJ. (2014). Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells 6:473–84.
   PubMedGoogle Scholar